Roche has admitted the infringement and validity of Amgen's EPO Patents. Court has entered Permanent Injunction and Roche would launch its pegylated-erythropoietin (peg-EPO) product in the
This blog serves the purpose of providing information and happenings in the Pharma IP milieu.
Thursday, December 24, 2009
Amgen and Roche end EPO patent infringement dispute
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment